378 related articles for article (PubMed ID: 22904642)
1. Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.
Yim KL
Cancer Manag Res; 2012; 4():207-14. PubMed ID: 22904642
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: A difficult conversion from biology to the clinic.
Fazio N
World J Clin Oncol; 2015 Dec; 6(6):194-7. PubMed ID: 26677429
[TBL] [Abstract][Full Text] [Related]
4. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
Capozzi M; Caterina I; De Divitiis C; von Arx C; Maiolino P; Tatangelo F; Cavalcanti E; Di Girolamo E; Iaffaioli RV; Scala S; Tafuto S;
Int J Surg; 2015 Sep; 21 Suppl 1():S89-94. PubMed ID: 26123382
[TBL] [Abstract][Full Text] [Related]
5. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2018; 211():101-123. PubMed ID: 30069763
[TBL] [Abstract][Full Text] [Related]
6. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors.
Beyens M; Vandamme T; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Mar; 26(3):R109-R130. PubMed ID: 32022503
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus.
Cen P; Amato RJ
Onco Targets Ther; 2012; 5():217-24. PubMed ID: 22870038
[TBL] [Abstract][Full Text] [Related]
8. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors.
Shida T; Kishimoto T; Furuya M; Nikaido T; Koda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Tanizawa T; Nakatani Y; Miyazaki M
Cancer Chemother Pharmacol; 2010 Apr; 65(5):889-93. PubMed ID: 19657638
[TBL] [Abstract][Full Text] [Related]
9. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
10. Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations.
Liu E; Marincola P; Oberg K
Therap Adv Gastroenterol; 2013 Sep; 6(5):412-9. PubMed ID: 24003341
[TBL] [Abstract][Full Text] [Related]
11. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR in carcinoid tumors.
Grozinsky-Glasberg S; Pavel M
Target Oncol; 2012 Sep; 7(3):189-95. PubMed ID: 22886906
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors.
Ge W; Zhou D; Zhu L; Song W; Wang W
J Cancer; 2018; 9(24):4783-4790. PubMed ID: 30588264
[TBL] [Abstract][Full Text] [Related]
14. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
15. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTOR pathways in human malignancies.
Fasolo A; Sessa C
Curr Pharm Des; 2012; 18(19):2766-77. PubMed ID: 22475451
[TBL] [Abstract][Full Text] [Related]
17. Everolimus in the management of metastatic neuroendocrine tumours.
Chan DL; Segelov E; Singh S
Therap Adv Gastroenterol; 2017 Jan; 10(1):132-141. PubMed ID: 28286565
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
[TBL] [Abstract][Full Text] [Related]
19. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
20. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
